Mozambique launches Brazil-funded drugs plant to battle HIV

July 21, 2012

Mozambique on Saturday launched a Brazilian funded pharmaceutical plant that will make anti-retroviral drugs to battle the HIV/AIDS scourge in the southern African country.

The factory -- built with $23 million in aid from Brazil and $4.5 million from that country's mining giant Vale -- will initially package drugs from Brazil but start producing the pills by the end of the year.

Mozambique has more than 2.5 million people living with HIV -- nearly 12 percent of the population -- but fewer than 300,000 of them now take anti-retroviral (ARV) drugs, according to the .

ARVs suppress the , reducing sickness and death rates as well as the transmission of the virus that causes AIDS.

Brazil's Vice President Michel Temer attended Saturday's launch of what is thought to be Africa's first fully public ARV factory in Matola, along with Mozambique's Industry and Commerce Minister Armando Inroga.

"As of now drugs which were manufactured in Brazil will be packaged here in Mozambique, certified and distributed to the Mozambican people," Temer said.

"There is an excellent partnership between the Brazilian and the Mozambican people and there is an absolute integration between the two countries in both public and private sectors."

In 2010 Brazil's then-president Luiz Inacio Lula da Silva visited the plant site and called it a "revolution" in Africa's fight against HIV/AIDS.

Brazil offers free ARV treatment to HIV-positive citizens, a programme that sparked controversy when it was announced in 1996 because of concerns about and violation of pharmaceutical copyright.

But it has since been praised as a model for the developing world. The World Bank estimates the free medicine saved more than half a million lives.

Mozambican technicians and other staff for the plant are now being trained, some of them in Brazil, through a partnership with the Brazilian public health institution A Fundacao Oswaldo Cruz.

Explore further: S.Africa in $208 mln AIDS drug venture with Swiss Lonza

Related Stories

S.Africa in $208 mln AIDS drug venture with Swiss Lonza

February 10, 2012
South Africa on Friday unveiled plans for a 1.6 billion rand ($208 million, 157 million euro) pharmaceutical plant, in a joint venture with Swiss biochemicals group Lonza to produce anti-AIDS drugs.

South Africa reports new success in saving newborns from HIV

July 19, 2012
About 117,000 babies were saved from HIV infection last year under South Africa's scheme to prevent mothers from passing on the disease during childbirth, health official said Thursday.

Sanofi teams up with India to make cheap ARVs in S.Africa

March 30, 2012
French pharmaceutical giant Sanofi has signed a partnership with India's Hetero to manufacture cheap anti-HIV drugs in South Africa, the company said on Friday.

Recommended for you

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

Heart toxin reveals new insights into HIV-1 integration in T cell genome

July 20, 2017
Human immunodeficiency virus (HIV)-1 may have evolved to integrate its genetic material into certain immune-cell-activating genes in humans, according to new research published in PLOS Pathogens.

Scientists capture first high-resolution image of key HIV protein transitional state

July 13, 2017
A new, three-dimensional snapshot of HIV demonstrates the radical structural transformations that enable the virus to recognize and infect host cells, according to a new study led by scientists at The Scripps Research Institute ...

Barrier to autoimmune disease may open door to HIV, study suggests

July 11, 2017
Researchers from the University of Colorado School of Medicine have discovered that a process that protects the body from autoimmune disease also prevents the immune system from generating antibodies that can neutralize the ...

Team tests best delivery mode for potential HIV vaccine

June 20, 2017
For decades, HIV has successfully evaded all efforts to create an effective vaccine but researchers at The Scripps Research Institute (TSRI) and the La Jolla Institute for Allergy and Immunology (LJI) are steadily inching ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.